Clinical trials: Obesity & Overweight
Healthy Volunteers, Overweight
A Research Study Looking at the Comparability (Bioequivalence) of Two Versions of Semaglutide
The study will look at how two different versions of semaglutide reach and stay in the blood after injection. The study aims to show similar levels of semaglutide in the blood when using the different versions.
- Conditions
- Healthy Volunteers, Overweight, Obesity
- Trial name
- NCT04228354
- Testing
- Semaglutide
- Where
- Germany
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Overweight or Obesity
Relative Bioavailability of First vs Second-Generation Formulations of HRS9531 Tablets in Obese or Overweight Subjects
This study aims to compare the relative bioavailability, safety and tolerability of the first-generation and second-generation formulations of HRS9531 tablets, as well as to explore the safety, tolerability and pharmacokinetic…
- Trial name
- NCT07150962
- Testing
- HRS-9531 Tablet
- Where
- China
- Volunteers
- 168 people
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Obesity
A Short-Term Study to Examine the Effects of ATHX-105 Phosphate on Weight Loss and Safety
This primary purpose of this study is to determine if ATHX-105 phosphate causes weight loss over a 12-week period.
- Trial name
- NCT00735683
- Testing
- ATHX-105 phosphate
- Sponsor
- Healios K.K.
Healthy, Obese
A Drug-Drug Interaction Study of Orforglipron (LY3502970) in Healthy Overweight and Obese Participants
The main purpose of this study is to determine effect of orforglipron capsule formulation on the amount of digoxin, rosuvastatin, acetaminophen, midazolam, and simvastatin (each given alone and together with orforglipron) that…
- Conditions
- Healthy, Obese, Overweight
- Trial name
- NCT06186622
- Testing
- Orforglipron, Simvastatin, Digoxin
- Where
- 2 sites in United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Obesity
Study to Explore the Safety and Efficacy of NT-0796 as an Adjunct to Semaglutide in Participants With Obesity (RESOLVE-2)
A Phase 2a randomized, double-blind, placebo-controlled, parallel-group, multicenter study to explore the safety and efficacy of NT-0796 as an adjunct to semaglutide in participants with obesity over a 6 months treatment period.
- Trial name
- RESOLVE-2 (NCT07220629)
- Testing
- NT-0796
- Where
- 9 sites in United States
- Volunteers
- 82 people
- Sponsor
- Rezera (formerly NodThera Limited)
Obesity, Type 2 Diabetes
EndoBarrier® SANS™ in Over-weight or Obese Type 2 Diabetic Subjects
This study will evaluate the safety and efficacy of the EndoBarrier® SANS™ in overweight and obese subjects with type 2 diabetes.
- Trial name
- NCT02443753
- Testing
- EndoBarrier SANS
- Where
- Malaysia
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Morphic Medical Inc.
Overweight , Obesity
A Study of Zovaglutide in Subjects With Overweight or Obesity (HORIZON-1)
This study will evaluate the percentage change in body weight from baseline and proportion of subjects achieving ≥ 5% weight loss from baseline after 52 weeks of treatment with Zovaglutide in subjects with overweight/obesity.
- Trial name
- NCT07230119
- Testing
- Zovaglutide dose 1, Zovaglutide dose 2
- Where
- 45 sites in China
- Volunteers
- 755 people
- Sponsor
- Beijing QL Biopharmaceutical Co.,Ltd
Healthy Participants
Relative Levels of BMS-986036 in Blood Plasma in Healthy, Overweight, and Obese Participants Following Subcutaneous Administration Via Auto-injector Versus Pre-filled Syringe
The purpose of this study is to develop an auto-injector (AI) device for the BMS-986036 subcutaneous formulation that can be self-administered conveniently by participants.
- Trial name
- NCT04493567
- Testing
- BMS-986036
- Where
- 2 sites in United States
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Overweight , Obesity
Phase 3 Study of MWN109 Injection in Participants With Overweight or Obesity
This is a phase 3, multicenter, randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of MWN109 injection in non-diabetic participants with overweight or obesity.
- Trial name
- NCT07778693
- Testing
- MWN109 1, MWN109 2, MWN109 3
- Where
- China
- Volunteers
- 760 people
- Sponsor
- Shanghai Minwei Biotechnology Co., Ltd
GERD, Gastroesophageal Reflux Disease
RELIEF Europe Study
The purpose of this study is to evaluate the LINX device in patients who have previously undergone laparoscopic sleeve gastrectomy (LSG) for obesity and have chronic gastroesophageal reflux disease (GERD).
- Conditions
- GERD, Gastroesophageal Reflux Disease, Obesity, LSG
- Trial name
- NCT02762487
- Testing
- The LINX® Reflux Management System
- Where
- 4 sites in Germany, Italy
- Volunteers
- 7 people
- Sponsor
- Torax Medical Incorporated
Type 2 Diabetes, Metabolic Syndrome
Clinical Study on the Effect of a Synbiotic on Body Fat Mass
In this trial the effect of a synbiotic consisting of the three different strains of Lactobacillus fermentum and acacia gum (gum arabic) on body fat mass, body weight, long-term glycemia, insulin resistance and other risk factors…
- Conditions
- Type 2 Diabetes, Metabolic Syndrome, Obesity, Abdominal, Obesity, Visceral
- Trial name
- NCT04754464
- Testing
- synbiotic, microcrystalline cellulose
- Where
- 2 sites in Austria, Germany
- Volunteers
- 120 people
- Sponsor
- Slimbiotics GmbH
Obesity, Diabetes Mellitus, Non-Insulin-Dependent
Obese Patients With Type 2 Diabetes
To assess the effect on weight loss and weight maintenance over a period of one year when prescribed with a hypocaloric diet in obese patients with Type 2 Diabetes
- Conditions
- Obesity, Diabetes Mellitus, Non-Insulin-Dependent, Obesity in Diabetes
- Trial name
- RIO-Diabetes (NCT00029848)
- Testing
- Rimonabant (SR141716)
- Where
- 55 sites in United States, Argentina and 9 more
- Volunteers
- 1,045 people
- Sponsor
- Sanofi
Obesity, Hypertension
Efficacy of Candesartan on Reducing Blood Pressure in Insulin-Resistant, Obese Patients With Hypertension.
The purpose of this study is to determine the efficacy of candesartan, once daily (QD), combined with hydrochlorothiazide to lower blood pressure in insulin-resistant, obese patients with hypertension.
- Trial name
- NCT00775814
- Testing
- Candesartan and Hydrochlorothiazide, Hydrochlorothiazide (HCT)
- Where
- 24 sites in Germany
- Volunteers
- 188 people
- Sponsor
- Takeda
Obesity
A Dose-finding Study to Evaluate the Change in Weight After Treatment With LIK066 in Japanese Patients With Obesity
The purpose of the study is to evaluate the efficacy, tolerability and safety of LIK066 to support dose selection for Phase 3 development in Japanese adults with obesity disease.
- Trial name
- NCT03320941
- Testing
- LIK066
- Where
- 24 sites in Japan
- Volunteers
- 126 people
- Sponsor
- Novartis Pharmaceuticals
Weight Loss
Safety and Efficacy of IQP- AK-102 in Reducing Body Weight
The individual ingredients in IQP-AK-102 have been widely used. Backed by data from several studies demonstrating their efficacy, we are conducting this study to look into the efficacy and safety of this novel combination of…
- Trial name
- NCT01905956
- Testing
- IQP-AK-102
- Where
- Germany
- Volunteers
- 119 people, healthy volunteers welcome
- Sponsor
- InQpharm Group
Obesity, Obesity, Abdominal
Immunometabolic Effects of Non-drug Strategies in the Clinical Management of Obesity: Translational Study
Forty women aged between 18 and 75 years-old with a BMI> 30kg/m2 are recruited to participate in the evaluation of their medical management.
- Conditions
- Obesity, Obesity, Abdominal, Obesity, Visceral, Female
- Trial name
- PPAR-NAPAS (NCT04436419)
- Testing
- Alpha lipoic acid (plus full hospitalization)
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Fauqué
Obesity/Overweight
Efficacy and Safety of ALT-801 in the Treatment of Obesity
This study will evaluate the efficacy and safety of ALT-801 once-weekly versus placebo as an adjunct to a reduced-calorie diet and increased physical activity in patients with obesity/overweight.
- Trial name
- NCT05295875
- Testing
- ALT-801
- Where
- 31 sites in United States
- Volunteers
- 391 people
- Sponsor
- Altimmune, Inc.
Overweight and Obesity
Safety and Feasibility Assessment of the Bio-electrical One Day Capsule System in Overweight and Class I Obese Participants
The study represents the first effort to prospectively investigate the Melcap's bio-electrical ingestible ODC system in human. The study goal is to evaluate the safety and feasibility of GES treatment in stomach and in the small…
- Trial name
- NCT03734081
- Testing
- ODC system (type 1 capsule), ODC system (type 2 capsule)
- Where
- Israel
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Melcap Systems Ltd.
Obesity, Diabetes Mellitus, Type 2
A Study of the Efficacy and Safety of Topiramate in Obese, Type 2 Diabetic Patients Inadequately Controlled on Sulfonylurea Therapy
The purpose of this study is to compare the effectiveness and safety of topiramate with placebo in the treatment of obesity and Type 2 diabetes mellitus in patients who have failed on sulfonylurea therapy.
- Conditions
- Obesity, Diabetes Mellitus, Type 2, Diabetes Mellitus, Adult-Onset
- Trial name
- NCT00231634
- Testing
- topiramate
- Volunteers
- 31 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Obesity
Comparison of MAG and Fish Oil Efficacy
A potential application for unstructured monoacylglycerol (MAG) containing long chain polyunsaturated fatty acids (LC-PUFA)can be to provide essential fatty acids to humans who chronically consume lipases inhibitor such as…
- Trial name
- NCT01797757
- Testing
- Fish oil enriched with EPA, MAG-EPA oil, Orlistat
- Where
- Switzerland
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Société des Produits Nestlé (SPN)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.